STL Volume 30 Number 2

Explore the safety and efficacy of roflumilast 0.3% foam, a novel PDE-4 inhibitor, for treating seborrheic dermatitis. This review evaluates clinical trial outcomes, tolerability, and advantages compared to traditional therapies, highlighting its role as an effective, once-daily non-steroidal treatment option.

Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option.

Update on Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™), Ustekinumab-stba SC/IV injection (Steqeyma®) and Nivolumab + hyaluronidase-nvhy for SC injection (Opdivo Qvantig™).